The rise of fluoroquinolone resistance: Fact or fiction

Journal of Chemotherapy

Volumn 14, Issue SUPPL. 3, 2002, Pages 31-41

  Ferraro, M J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Fluoroquinolones; Ketolide; PROTEKT; Quinolones; Resistance to quinolones; Telithromycin

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CANADA; DRUG ACTIVITY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; EMPIRICISM; GRAM NEGATIVE BACTERIUM; HONG KONG; INFORMATION PROCESSING; MULTIDRUG RESISTANCE; NONHUMAN; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0036661170     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1120009x.2002.11782350     Document Type: Article

References (40)

1. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000; 16: 5-15.
2. Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999; 14: 221-229.
3. Murray CJL, Lopez AD. The global burden of disease. A comprehensive assessment of mortality and disability from disease, injuries and risk factors in 1990 and projected to 2020. Harvard University Press, Boston, MA, 1998.
4. Mandell L. Community-acquired pneumonia: etiology, epidemiology, and treatment. Chest 1995; 108, Suppl: 35S-42S.
5. Macfarlane J, Boswell T, Douglas G et al. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 7, Suppl IV.
6. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of S. pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998; 27: 764-770.
7. World Health Organisation. Containing antimicrobial resistance: review of the literature and report of a WHO workshop on the development of a global strategy for the containment of antimicrobial resistance (report no. WHO/CDS/CSR/DRS/99.2). World Health Organisation, Geneva, 1999.
8. Garcia-Rodriguez JA, Munoz Bellido JL. The role of fluoroquinolones in respiratory tract infections: community-acquired pneumonia. Int J Antimicrob Agents 2000; 16: 281-285.
9. Honeybourne D. Community-acquired pneumonia in ambulatory patients: relative importance of atypical pathogens. Int J Antimicrob Agents 2001; 18, Suppl 1: S57-S61.
10. Carbon C, Ariza H, Rabie WJ, Salvarez CR, Elkharrat D, Rangaraj M. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia. Clin Microbiol Infect 1999; 5: 724-732.
11. Fogarty C, Grossman R, Williams J, Haverstock D, Church D for the Community-Acquired Pneumonia Study Group. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999; 16: 748-763.
12. Chen DK, McGeer A, de Azavedo JC, Low DE and the Canadian Bacterial Surveillance Network. Decreased susceptibility of S. pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-239.
13. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-750.
14. Clark DW, Layton D, Wilton LV, Pearce GL, Shakir SA. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the drug safety research unit prescription monitoring database. Drug Safety 2001; 24: 1143-1154.
15. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 10 (2): 253S-272S.
16. Lee YL, Cesario T, McCauley V, Flionis L, Pax A, Thrupp L. Low-level colonisation and infection with ciprofloxacin-resistant gram-negative bacilli in a skilled nursing facility. Am J Infect Contr 1998; 26: 552-557.
17. Sahm DF, Critchley IA, Kelly LJ et al. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob Agents Chemother 2001; 45, 1: 267-274.
18. Richard P, Delangle MH, Raffi F, Espaze E, Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001; 32: 162-166.
19. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347-382.
20. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730-1754.
21. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31: 383-421.
22. European Study on Community-acquired Pneumonia (ESOCAP) Committee: Guidelines for the management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11: 986-991.
23. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7: 337-341.
24. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797-799.
25. Davies T, Goering RV, Lovgren M, Talbot JA, Appelbaum PC. Molecular epidemiological survey of penicillin-resistant Streptococcus pneumoniae from Asia, Europe and North America. Diagn Microbiol Infect Dis 1999; 34: 7-12.
26. McGee L, Goldsmith CE, Klugman KP. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antimicrob Chemother 2002; 49: 173-176.
27. Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Ferraro MJ, Tenover FC. Activities of clinafloxacin, gatifloxacin, gemifloxacin and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 2962-2968.
28. st Interscience Conference on Antimicrobial Agents and Chemotherapy 2001, Chicago, IL.
29. Ho PL, Yung RWH, Tsang DNC et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48: 659-665.
30. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, 1998, 1999, 2000. http://www.cdc.gov/ncidod/dbmd/abcs/survreports
31. th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000, Toronto, Ontario.
32. Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, Dahm D. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother 1999; 44: 749-759.
33. th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000 Toronto, Ontario.
34. Thomson CJ. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J Antimicrob Chemother 1999; 43, Suppl A: 31-40.
35. Pea C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995; 39: 520-524.
36. Barry AL, Fuchs PC, Brown SD. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quin-upristin-dalfopristin), a macrolide (erythromycin) and a lincosamide (clindamycin). Antimicrob Agents Chemother 1998; 42: 945-946.
37. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998; 42: 624-630.
38. Bébéar CM, Renaudin H, Aydin MD, Chantot JF, Bébéar C. In vitro activity of ketolides against mycoplasmas. J Antimicrob Chemother 1997; 39; 669-670.
39. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42: 1515-1516.
40. Schulin T, Wennersten CB, Ferraro MJ, Moellering RC, Eliopoulous GM. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998; 42: 1520-1523.